Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 75   

Articles published

ARNA 4.02 -0.08 (-1.95%)
price chart
Why Need to Watch: Vale S.A. (NYSE:VALE), Arena Pharmaceuticals, Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) currently has a Zacks Rank #3 (Hold). On last trading day Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) decreased -2.58% to close at $4.16. Its volatility for the week is 7.64% while volatility for the month is ...
Did VIVUS and Arena Pharmaceuticals Just Turn the Corner? (ARNA, VVUS)
Well, it was nowhere close to the way investors of VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) would have envisioned it happening two years ago, in terms of time or reason.
NASDAQ Stocks With High Volumes: EMCORE Corporation(NASDAQ:EMKR ...  GSPInsider
Gainers at NASDAQ: VIVUS Inc. (NASDAQ:VVUS), Arena Pharmaceuticals ...  WallStreet Scope
Related articles »  
Belviq Advertising Sees Major Shift
The anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) is finally seeing the type of action in the advertising space that investors can quantify as a compelling shift.
Related articles »  
Orexigen Therapeutics Stumbles Off the Edge of a Cliff (ARNA, VVUS, OREX)
On the off chance you need a reminder, Orexigen Therapeutics, Inc. was greatly ballyhooed heading into last week's decision day from the Food and Drug Administration.
Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away  Seeking Alpha (registration)
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Obesity Pill Approval Fails to ...  BasicsMedia
Related articles »  
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax ...
Arena Pharmaceuticals Inc.'s stock advanced 1.76%, to close Thursday's session at $4.05, after oscillating between $3.93 and $4.07.
Related articles »  
Trader's Recap: Arena Pharmaceuticals (NASDAQ:ARNA), Huntington ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that the company is scheduled to present a corporate overview and update at the NewsMakers in the Biotech Industry conference on Friday, September 26, 2014, at 11:30 a.m.
Related articles »  
Hot Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Galena ...
On 4 September Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) said that stock analysts at Credit Suisse assumed coverage on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a report issued on Thursday. The firm set an �underperform� rating on ...
Related articles »  
Don't Miss : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Caterpillar Inc ...
Contrave is a combination of two Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Vivus Inc. drugs that were approved by the FDA in 2012, ABC News reports, after having spent 13 years without approving any weight-loss medication.
Stock Runners: Arena Pharmaceuticals (NASDAQ:ARNA), AT&T, Inc. (NYSE:T ...
On 1 AUG Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Friday. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status
Arena Pharmaceuticals, Inc. (ARNA) announced that its pulmonary arterial hypertension (PAH) candidate APD811 has received orphan drug status from the FDA.